ArticleBMC cancer2025
Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMuscle-invasive urothelial carcinoma (MIUC) poses higher risks of recurrence and metastasis compared with non-muscle-invasive urothelial carcinoma (NMIUC). However, difficulties in early detection and the invasive nature of current diagnostic procedures. Using next-generation sequencing (NGS), we aimed to profile comprehensive surveillance of urinary microRNAs (miRNAs) as a promising non-invasive tool for assessing urothelial carcinoma (UC) and identify differentially expressed miRNAs (DEmiRNAs) in patients with MIUC or NMIUC, providing insights into UC progression and molecular mechanisms in Taiwanese patients. We analyzed the clinical differences between patients with MIUC or NMIUC in treatment-naïve patients.
methodsUrinary miRNAs were profiled using NGS. DEmiRNAs were identified with DESeq2, and target prediction was performed using TarBase-v9.0 and DIANA-microT. Enrichment analysis was conducted with the miEAA tool to link DEmiRNAs to biological pathways and processes, focusing on the KEGG pathways and Gene Ontology (GO) annotations.
resultsAmong the 52 participants, significantly more patients with MIUC used herbal medicines compared with the NMIUC group (p = 0.027). A total of 1,967 DEmiRNAs were detected comprehensively, with 691 upregulated and 232 downregulated in MIUC versus NMIUC. Notably, hsa-miR-3168 exhibited the highest upregulation (10.2-fold), while hsa-miR-511-3p was the most downregulated (9.32-fold). KEGG analysis revealed that upregulated DEmiRNAs were most enriched in amino acid biosynthesis pathways, while downregulated DEmiRNAs were associated with the Hedgehog signaling pathway.
conclusionsThis study highlights urinary DEmiRNAs detected via NGS as a potential non-invasive diagnostic tool. Pathway analyses of DEmiRNAs provided valuable insights into UC progression and offers opportunities for future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.